Royalty Pharma chief executive Pablo Legorreta is telling Elan's shareholders to keep their options open - asking them to align with his company's offer for the Dublin-based drug firm.
Legorreta has been chasing approval from investors ever since launching a hostile takeover bid in the wake of Elan's decision to sell its stake in the multiple sclerosis drug Tysabri to Biogen as part of a restructuring of the business.
Elan has been furious in its...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team